Umesh Modi is a chartered accountant, and Pamini Jatheeskumar is a chartered certified accountant at Silver Levene...
  Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead...
Don Lavoie is alcohol programme manager at Public Health England and Gul Root is lead pharmacist, Health and Wellbeing Directorate, Public Health England
More inWhite Papers  

almotriptanJanuary 5 2015

Teva has launched generic almotriptan 12.5mg film-coated tablets, following the expiry of the patent on Almogran from Almirall Ltd.

The prescription-only product is available in three pack sizes - 3s, 6s and 9s - and is indicated for the acute treatment of the headache phase of migraine attacks with or without aura.

Kim Innes, Teva’s Commercial Director said: “We are pleased to be able to add almotriptan tablets to our portfolio. Bringing our generic version of medicine to market on the first available day following expiry of the patent on the branded medicine enables the potential savings to the NHS to be realised immediately.”

Teva points out: “There are 190,000 migraine attacks every day in the UK, and there are more people who suffer with migraine than people with diabetes, asthma and epilepsy combined, according to figures from the Migraine Trust.”


Teva announcement

Teva almotriptan product information

July 31 2018 General practices employing pharmacists are citing improved capacity to see patients and workload changes as the main benefits of the scheme.
July 25 2018 Switching to sulfonylureas in type 2 diabetes has been linked with an increased risk of complications compared with staying on metformin, a BMJ study has concluded. However, the study has...